Nephros (NEPH) Projected to Post Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $3.8660 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.04. Nephros had a net margin of 7.95% and a return on equity of 14.89%. The company had revenue of $4.40 million during the quarter, compared to analyst estimates of $3.60 million.

Nephros Stock Performance

Shares of NEPH opened at $5.45 on Thursday. The firm has a market cap of $57.77 million, a P/E ratio of 45.42 and a beta of 1.32. The business has a 50-day moving average of $4.61 and a 200 day moving average of $3.67. Nephros has a fifty-two week low of $1.39 and a fifty-two week high of $5.98.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nephros stock. Topline Capital Management LLC increased its holdings in Nephros Inc. (NASDAQ:NEPH) by 13.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 477,449 shares of the company’s stock after purchasing an additional 55,360 shares during the period. Topline Capital Management LLC owned 4.50% of Nephros worth $1,953,000 as of its most recent SEC filing. Institutional investors and hedge funds own 41.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Maxim Group upped their price objective on shares of Nephros from $4.50 to $6.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Wall Street Zen upgraded Nephros to a “strong-buy” rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Nephros in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.50.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.